ClinicalTrials.gg
Active, not recruitingNCT05156281REMODEL-2Updated Nov 12, 2026

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

A Phase 3 interventional study of Remibrutinib and Teriflunomide in Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 223 sites in 27 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Title changed3 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,007
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

Read the detailed description

The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.

The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).

The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.

A second study of identical design (CLOU064C12301) will be conducted simultaneously. Both studies will be conducted globally and data from the two studies will be pooled for some of the endpoints.

02

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

Keywords

  • MS
  • RMS
  • RRMS
  • active secondary progressive multiple sclerosis SPMS
  • remibrutinib
  • LOU064
  • teriflunomide
  • adult
  • relapse
  • Expanded Disability Status Scale
  • T2 lesions
  • T1 lesions
  • GD- enhancing MRI
  • Neurofilament light chain
  • McDonald diagnostic criteria
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • 18 to 55 years of age
  • Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
  • At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
  • EDSS score of 0 to 5.5 (inclusive)
  • Neurologically stable within 1 month

Exclusion Criteria:

  • Diagnosis of primary progressive multiple sclerosis (PPMS)
  • Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening
  • History of CNS disease other than MS
  • Ongoing substance abuse (drug or alcohol)
  • History of of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),
  • Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML
  • suicidal ideation or behavior
  • Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence
  • Participants who have had a splenectomy
  • Active clinically significant systemic bacterial, viral, parasitic or fungal infections
  • Positive results for syphilis or tuberculosis testing
  • Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral
  • Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.
  • Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for antibody
  • History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis (including all classes) or hepatic failure or any chronic liver or biliary disease.
  • History of severe renal disease or creatinine level
  • Participants at risk of developing or having reactivation of hepatitis
  • Hematology parameters at screening:

    • : \< 10 g/dl (\<100g/L)
    • : \< 100000/mm3 (\<100 x 109/L)
    • Absolute lymphocyte count \< 800/mm3 (\<0.8 x 109/L)
    • White blood cells: \<3 000/mm3 (\<3.0 x 109/L)
    • Neutrophils: \< 1 500/mm3 (\<1.5 x 109/L)
    • B-cell count \< 50% lower limit of normal (LLN) or total IgG \& total IgM \< LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
  • History or current diagnosis of significant abnormalities
  • Resting ≥450 msec (male) or ≥460 msec (female) at pre-treatment as per central ECG reading at screening visit
  • Use of other drugs
  • Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,
  • History of gastrointestinal bleeding
  • Major surgery within 8 weeks prior to screening
  • History of to any of the study drugs or
  • Pregnant or nursing (lactating) female participants, prior to randomization
  • Women of not using highly effective
  • Sexually active males not agreeing to use condom
  • Have received any live or within 6 weeks of randomization or requirement to receive these vaccinations during study
  • Use of strong inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization

Inclusion to Extension part:

  • Participants who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,007 participants (actual)

Study arms

  • Experimental
    Remibrutinib - Core

    Remibrutinib tablet and matching placebo of teriflunomide capsule

    Drug: Remibrutinib

  • Active comparator
    Teriflunomide - Core

    Teriflunomide capsule and matching placebo remibrutinib tablet

    Drug: Teriflunomide

  • Experimental
    Remibrutinib - Extension

    Participants on remibrutinib in Core will continue on remibrutinib tablet

    Drug: Remibrutinib

  • Experimental
    Remibrutinib - Extension (on teriflunomide in Core)

    Participants on teriflunomide in Core will switch to remibrutinib tablet

    Drug: Remibrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Annualized relapse rate (ARR) of confirmed relapses [Core Part]

    ARR is the average number of confirmed MS relapses in a year

    Time frame: From Baseline, up to 30 months

Secondary outcomes

  1. Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) [Core Part] (pooled data)

    Time to 3-month confirmed disability progression (3mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months

    Time frame: Baseline up to 30 months

  2. Time to 6-month confirmed disability progression (6mCDP) on EDSS [Core Part] (pooled data)

    Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months

    Time frame: Baseline up to 30 months

  3. Annualized rate of new or enlarging T2 lesion [Core Part]

    Number of new/newly enlarged T2 lesions per year

    Time frame: Baseline up to 30 months

  4. Neurofilament light chain (Nfl) [Core Part]

    Neurofilament light chain (NfL) concentration in serum

    Time frame: Baseline up to 30 months

  5. Number of Gd-enhancing T1 lesions per MRI scan [Core Part]

    Average number of Gd-enhancing T1 lesions per scan

    Time frame: Baseline up to 30 months

  6. Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3) [Core Part] (pooled data)

    Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI

    Time frame: Baseline up to 30 months

  7. Time to first confirmed relapse [Core Part]

    Change in the Expanded Disability Status Scale (EDSS), an increase of at least 0.5 points on the EDSS (total) score, or an increase of at least 1 point on at least two functional scores (FSs), or an increase of at least 2 points on at least one FS, excluding changes involving bowel/bladder or cerebral FS, compared to the previous available rating.

    Time frame: Baseline up to 30 months

  8. Time to 6-month confirmed disability improvement (6mCDI) on EDSS [Core Part] (pooled data)

    Decrease in Expanded Disability Status Scale Score (EDSS) which is sustained for at least 6 months

    Time frame: Baseline up to 30 months

  9. Time to 3-months confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) independent of relapse activity (PIRA) [Core Part] (pooled data)

    Time to 3-month confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months or 6 months, respectively, without an on-study relapse before or on the day of a progression eve

    Time frame: Baseline up to 30 months

  10. Change from baseline in the Symbol Digit Modalities Test (SDMT) [Core Part] (pooled data)

    Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening

    Time frame: Baseline up to 30 months

  11. Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW) [Core Part] (pooled data)

    The patient walking speed to cover 25-foot distance is recorded in seconds. Longer time indicates poorer lower limb function. 20% worsening is defined as 20% increase from baseline T25FW score

    Time frame: Baseline, up to 30 months

  12. Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT) (pooled data) [Core Part] (pooled data)

    The patient's right and left arm function to peg 9 holes measured in seconds. Longer time indicates poorer upper limb function. 20% worsening is defined as 20% increase from baseline 9HPT score in at least one hand (average of two trials per hand)

    Time frame: Baseline up to 30 months

  13. Time to composite 6-month confirmed disability Progression (CDP) [Core Part] (pooled data)

    The composite involves CDP and worsening by at least 20% in T25FW and 9HPT

    Time frame: Baseline up to 30 months

  14. Change from Baseline in T2 lesion volume [Core Part]

    Change from baseline in total T2 lesion volume.

    Time frame: Baseline up to 30 months

  15. Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Core Part]

    29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life

    Time frame: Baseline up to 30 months

  16. Number of participants with Adverse events and Serious adverse events(SAE) [Core Part]

    Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating

    Time frame: Baseline up to 30 months

  17. Pharmacokinetics of remibrutinib [Core Part]

    Blood concentrations of remibrutinib

    Time frame: Month 1, Month 6

  18. Number of participants with Adverse events and Serious adverse events (SAE) [Extension Part]

    Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating

    Time frame: Day 1 Extension up to 5 years

  19. Annualized relapse rate (ARR) of confirmed relapses [Extension Part]

    ARR is the average number of confirmed MS relapses in a year

    Time frame: Day 1 Extension up to 5 years

  20. Annualized rate of new or enlarging T2 lesion [Extension Part]

    Number of new/newly enlarged T2 lesions per year

    Time frame: Day 1 Extension up to 5 years

  21. Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]

    Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months

    Time frame: Day 1 Extension up to 5 years

  22. Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]

    Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening

    Time frame: Day 1 Extension up to 5 years

  23. Neurofilament light chain (NfL) [Extension Part]

    Neurofilament light chain (NfL) concentration in serum

    Time frame: Day 1 Extension up to 5 years

  24. Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part]

    29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life

    Time frame: Day 1 Extension up to 5 years

07

Study locations

223 sites
  • Ctr for Neurology and Spine
    Phoenix, Arizona 85018, United States
  • Vladimir Royter MD APMC
    Hanford, California 93230, United States
  • VA Greater LA Healthcare System
    Los Angeles, California 90073, United States
  • Regina Berkovich MD PhD Inc
    West Hollywood, California 90048, United States
  • CU Anschutz Med Campus
    Aurora, Colorado 80045, United States
  • Colorado Neurological Research PC
    Denver, Colorado 80210, United States
  • New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • Georgetown University Hospital Research
    Washington D.C., District of Columbia 20007, United States
  • Georgetown University Hospital
    Washington D.C., District of Columbia 20007, United States
  • Nova Clinical Research LLC
    Bradenton, Florida 34209, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Memorial Healthcare System
    Hollywood, Florida 33021, United States
  • Neurology Associates PA
    Maitland, Florida 32751, United States
  • Gables Neurology
    Miami, Florida 33133, United States
  • UM Department Of Neurology
    Miami, Florida 33136, United States
  • Aqualane Clinical Research
    Naples, Florida 34105, United States
  • Advent Health Orlando
    Orlando, Florida 32803, United States
  • Humanity Clinical Research
    Pembroke Pines, Florida 33024, United States
  • Emerald Coast Neurology
    Pensacola, Florida 32514, United States
  • Brain and Spine Institute
    Port Orange, Florida 32127, United States
  • Vero Beach Neurology
    Vero Beach, Florida 32960, United States
  • Conquest Research
    Winter Park, Florida 32789, United States
  • Methodist Neuroscience Institute
    Merrillville, Indiana 46410, United States
  • University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • Baptist Physicians Lexington
    Nicholasville, Kentucky 40356, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Clinre Comprehensive Neurology
    Frederick, Maryland 21702, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Kansas City VA Medical Center
    Kansas City, Missouri 64128, United States
  • South Shore Neurologic Associates
    Patchogue, New York 11772, United States
  • University Of NC At Chapel Hill
    Chapel Hill, North Carolina 27599-9500, United States
  • Piedmont HealthCare
    Charlotte, North Carolina 28210, United States
  • The Boster Ctr for MS
    Columbus, Ohio 43235, United States
  • Neurology Diagnostics Inc
    Dayton, Ohio 45408, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Premier Neurology
    Greenville, South Carolina 29605, United States
  • Metrolina Neurological Associates PA
    Old Point Station, South Carolina 29707, United States
  • Sibyl Wray MD Neurology PC
    Knoxville, Tennessee 37922, United States
  • Carum Research
    Dallas, Texas 75231, United States
  • Med Research Inc
    El Paso, Texas 79935, United States
  • Lone Star Neurology
    Frisco, Texas 75035, United States
  • UT Health MARC Medical Arts and Research Center
    San Antonio, Texas 78229, United States
  • Lonestar Neurology of San Antonio
    San Antonio, Texas 78258, United States
  • Texas Institute for Neurological Disorders
    Sherman, Texas 75092, United States
  • Baylor Scott and White
    Temple, Texas 76508, United States
  • Virginia Mason Medical Centre
    Seattle, Washington 98101, United States
  • University of Washington MS Clinic
    Seattle, Washington 98133, United States
  • Elligo Health Research
    Crab Orchard, West Virginia 25827, United States
  • Ascension St Francis Center
    Milwaukee, Wisconsin 53215, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Novartis Investigative Site
    Bombal, Mendoza Province M5500DXO, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000BZL, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000DSW, Argentina
  • Novartis Investigative Site
    San Miguel de, Tucumán Province T4000, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1012AAR, Argentina
  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
  • Novartis Investigative Site
    Córdoba, X5004CDT, Argentina
  • Novartis Investigative Site
    Vitória, Espírito Santo 29055-450, Brazil
  • Novartis Investigative Site
    Brasília, Federal District 70200-730, Brazil
  • Novartis Investigative Site
    Curitiba, Paraná 81210-310, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90430-001, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90560-032, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90620-130, Brazil
  • Novartis Investigative Site
    Joinville, Santa Catarina 89202-165, Brazil
  • Novartis Investigative Site
    São Paulo, 01240-020, Brazil
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Sofia, 1309, Bulgaria
  • Novartis Investigative Site
    Sofia, 1407, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Edmonton, Alberta T6G 2B7, Canada
  • Novartis Investigative Site
    Burnaby, British Columbia V5G 2X6, Canada
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 4K4, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Lévis, Quebec G6W 0M5, Canada
  • Novartis Investigative Site
    Montreal, Quebec H4A 3T2, Canada
  • Novartis Investigative Site
    Québec, Quebec G1J 1Z4, Canada
  • Novartis Investigative Site
    Saint-Jérôme, Quebec J7Z 5T3, Canada
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
  • Novartis Investigative Site
    Wuhan, Hubei 430060, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
  • Novartis Investigative Site
    Yinchuan, Ningxia 750004, China
  • Novartis Investigative Site
    Taiyuan, Shanxi 030001, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310006, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310016, China
  • Novartis Investigative Site
    Wenzhou, Zhejiang 325000, China
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Shanghai, 200040, China
  • Novartis Investigative Site
    Zagreb, Croatia 10000, Croatia
  • Novartis Investigative Site
    Split, HRV 21000, Croatia
  • Novartis Investigative Site
    Varaždin, HRV 42000, Croatia
  • Novartis Investigative Site
    Vukovar, Vukovar 32000, Croatia
  • Novartis Investigative Site
    Zagreb, 10000, Croatia
  • Novartis Investigative Site
    Brno, 602 00, Czechia
  • Novartis Investigative Site
    Hradec Králové, 500 05, Czechia
  • Novartis Investigative Site
    Teplice, 415 29, Czechia
  • Novartis Investigative Site
    Tallinn, 11315, Estonia
  • Novartis Investigative Site
    Tartu, 50406, Estonia
  • Novartis Investigative Site
    Limoges, Haute Vienne 87000, France
  • Novartis Investigative Site
    Toulon, Val De Marne 83800, France

Showing the first 100 of 223 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Wiendl H, Bermel R, Airas L, Chitnis T, Nakahara J, Williams M, Adamczyk-Sowa M, Piasecka-Stryczynska K, Zielman R, Dunphy S, Panchaud N, Cai M, Xi J, Loop B, Su W, Willi R, Montalban X; REMODEL Investigators. Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials. Lancet. 2026 Oct 23:S0140-6736(26)02058-1. doi: 10.1016/S0140-6736(26)02058-1. Online ahead of print. PubMed 42915009 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jul 2026, 55 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2021
First posted
Dec 14, 2021
StartActual
Dec 13, 2021
Primary completionActual
Jul 22, 2026
CompletionEst.
Oct 30, 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (2 Japan, 1 United States)
  • Carum Research · Dallas, United States
  • Novartis Investigative Site · tabashi City, Japan
  • Novartis Investigative Site · Niigata, Japan
Show 3 removed
  • Neurology Consultants Of Dallas PA · Dallas, United States
  • Novartis Investigative Site · Niigata, Japan
  • Novartis Investigative Site · Itabashi-ku, Japan
Nov 12, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42915009 ↗
Nov 12, 2026
Title
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42915009 ↗
    3 sites added, 3 sites removed
    Show 3 added (2 Japan, 1 United States)
    • Carum Research · Dallas, United States
    • Novartis Investigative Site · tabashi City, Japan
    • Novartis Investigative Site · Niigata, Japan
    Show 3 removed
    • Neurology Consultants Of Dallas PA · Dallas, United States
    • Novartis Investigative Site · Niigata, Japan
    • Novartis Investigative Site · Itabashi-ku, Japan
    Title Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05156281
Responsible party
Sponsor
First posted
Dec 14, 2021
Start date
Dec 13, 2021
Primary completion
Jul 22, 2026
Completion
Oct 30, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion